

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

<p style="text-align: center;">Licensee</p> <p>1. Community Howard Regional Health, Inc.</p> <p>2. 3500 S. LaFountain St. Kokomo, IN 46902</p>	<p>In accordance with letter dated April 11, 2019.</p> <p>3. License number: 13-13028-02 is amended in its entirety to read as follows:</p>	<p>4. Expiration Date: June 30, 2024</p> <p>5. Docket No.: 030-13342 Reference No.: 030-38264/13-32789-01</p>
--	---	---

<p>6. Byproduct, source, and/or special nuclear material</p> <p>A. Any byproduct material permitted by 10 CFR 35.100</p> <p>B. Any byproduct material permitted by 10 CFR 35.200</p> <p>C. Any byproduct material permitted by 10 CFR 35.300</p>	<p>7. Chemical and/or physical form</p> <p>A. Any</p> <p>B. Any</p> <p>C. Any</p>	<p>8. Maximum amount that licensee may possess at any one time under this license</p> <p>A. As Needed</p> <p>B. As Needed</p> <p>C. 2 curies total</p>	<p>9. Authorized use</p> <p>A. For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.</p> <p>B. For use in imaging and localization studies permitted by 10 CFR 35.200.</p> <p>C. For any use permitted by 10 CFR 35.300.</p>
--	---	--	--

CONDITIONS

10. A. Licensed material may be used or stored at the licensee's facilities located at 3500 South LaFountain Street, Kokomo, Indiana.
- B. Licensed material listed in Subitem No. 6.B., limited to technetium-99m for sentinel node biopsies, may be used or stored at the licensee's facilities located at 3503 South Reed Road, Kokomo, Indiana.

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number
13-13028-02

Amendment No. 56

Docket or Reference Number
030-13342 030-38264/13-32789-01

11. The Radiation Safety Officer (RSO) for this license is Edward E. Wroblewski, M.A., DABSNM.

12. Licensed material shall only be used by, or under the supervision of:

A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.

B. The following individuals are authorized users for the material and medical uses as indicated:

Authorized User(M.D.,D.O.,etc.)

Material and Use

Andrew V. Barger, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Mary E. Below, M.D.

10 CFR 35.100 and 35.200

Thomas G. Belt, M.D.

10 CFR 35.100, 35.200, and 35.300

Jonathon Berger, M.D.

10 CFR 35.100 and 35.200

James Blahunka, M.D.

10 CFR 35.100, 35.200, and 35.300

James R. Bognanno, M.D.

10 CFR 35.100 and 35.200

John L. Bormann, M.D.

10 CFR 35.100, 35.200, and 35.300

Gitasree Borthakur, M.D.

10 CFR 35.300 (limited to oral administration of sodium iodide I-131)

Daniel Branam, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131 in quantities of 33 millicuries or less)

Christian M. Fisher, M.D.

10 CFR 35.100 and 35.200

Jeremy D. Gilliam, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131)

Brett A. Hagedorn, M.D.

10 CFR 35.100, 35.200, and 35.300

Stefan Andrew Hoff, M.D.

10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131)

David B. Janizek, M.D.

10 CFR 35.100, 35.200, and 35.300

Kenyon K. Kopecky, M.D.

10 CFR 35.100, 35.200, and 35.300

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**

License Number

13-13028-02

Docket or Reference Number

030-13342

030-38264/13-32789-01

Amendment No. 56

Authorized User(M.D.,D.O.,etc.)Material and Use

Christopher Michael Kowalski, M.D.	10 CFR 35.100 and 35.200
David Kurlander, M.D.	10 CFR 35.100, 35.200, and 35.300
Michael L. Lutz, M.D.	10 CFR 35.100, 35.200, and 35.300
Rajesh Mallela, M.D.	10 CFR 35.200
Gregory A. Merchun, M.D.	10 CFR 35.100, 35.200, and 35.300
Thomas N. Murphy, M.D.	10 CFR 35.100 and 35.200
Mark Joseph Paluszny, M.D.	10 CFR 35.100 and 35.200
Michael E. Parker, M.D.	10 CFR 35.100, 35.200, and 35.300
John Pasalich, M.D.	10 CFR 35.100, 35.200, and 35.300
Dakshesh S. Patel, M.D.	10 CFR 35.100 and 35.200
Orrin W. Perkins, M.D.	10 CFR 35.100, 35.200, and 35.300
Randall J. Phillips, M.D.	10 CFR 35.100, 35.200, and 35.300
Anil K. Ranginani, M.D.	10 CFR 35.100 and 35.200
John Rock, M.D.	10 CFR 35.100 and 35.200
Richard L. Scales, M.D.	10 CFR 35.100 and 35.200
Richard W. Sibley, M.D.	10 CFR 35.100, 35.200, and 35.300
Rik Stephens, M.D.	10 CFR 35.100, 35.200, and 35.300
Stephan M. Stockberger, Jr., M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to oral administration of sodium iodide I-131)
Andre Byard Stovall, M.D.	10 CFR 35.100, 35.200, and 35.300
Michael L. Swack, M.D.	10 CFR 35.100 and 35.200
Perry E. Wethington, M.D.	10 CFR 35.100 and 35.200

**MATERIALS LICENSE
SUPPLEMENTARY SHEET**License Number
13-13028-02

Amendment No. 56

Docket or Reference Number
030-13342 030-38264/13-32789-01

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

- A. Letter dated December 16, 2013 (ML14023A635)
- B. Letter dated September 24, 2015 (ML15288A522)
- C. Letter dated May 9, 2016 (ML16139A407)
- D. Letter dated June 28, 2016 (ML16181A197)
- E. Letter dated April 13, 2017 (ML17103A558)
- F. Letter dated April 11, 2019 (ML19106A220)
- G. Letter dated May 29, 2019 (ML19154A096)

Date: JUN 10 2019

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

By: Magdalena R. Grylak
Magdalena R. Grylak
Region 3